Incidence and outcome of male breast cancer: an international population-based study

Miao, Hui; Verkooijen, Helena; Chia, Kee-Seng; Bouchardy Magnin, Christine; Pukkala, Eero; Larønningen, Siri; Mellemkjær, Lene; Czene, Kamila; Hartman, Mikael

doi:10.1200/JCO.2011.36.8902

Scientific article

English

Incidence and outcome of male breast cancer: an international population-based study

ContributorsMiao, Hui; Verkooijen, Helena; Chia, Kee-Seng; Bouchardy Magnin, Christine; Pukkala, Eero; Larønningen, Siri; Mellemkjær, Lene; Czene, Kamila; Hartman, Mikael

Published inJournal of clinical oncology, vol. 29, no. 33, p. 4381-4386

Publication date2011

Abstract

Male breast cancer is a rare disease with an incidence rate less than 1% of that of female breast cancer. Given its low incidence, few studies have assessed risk and prognosis.

Keywords

Adult
Aged
Breast Neoplasms/epidemiology/mortality
Breast Neoplasms, Male/epidemiology/mortality
Female
Humans
Incidence
Male
Middle Aged
Registries
Sex Factors

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de santé et médecine communautaires / Institut de santé globale / Registre genevois des tumeurs

Research groups

Groupe Bouchardy Magnin Christine (Registre genevois des tumeurs) (532)

Citation (ISO format)

MIAO, Hui et al. Incidence and outcome of male breast cancer: an international population-based study. In: Journal of clinical oncology, 2011, vol. 29, n° 33, p. 4381–4386. doi: 10.1200/JCO.2011.36.8902

Article (Published version)

Identifiers

PID : unige:24417
DOI : 10.1200/JCO.2011.36.8902
PMID : 21969512

Journal ISSN0732-183X

965views

1652downloads

Creation20/11/2012 14:28:00

First validation20/11/2012 14:28:00

Update14/03/2023 17:46:47

Status update14/03/2023 17:46:47

Last indexation30/10/2024 08:01:42

Archive ouverte UNIGE

Incidence and outcome of male breast cancer: an international population-based study

Male breast cancer is a rare disease with an incidence rate less than 1% of that of female breast cancer. Given its low incidence, few studies have assessed risk and prognosis.

Technical informations